<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00851136</url>
  </required_header>
  <id_info>
    <org_study_id>APM4566g</org_study_id>
    <nct_id>NCT00851136</nct_id>
  </id_info>
  <brief_title>A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)</brief_title>
  <official_title>A Phase Ib Study of the Safety and Pharmacokinetics of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This will be a multicenter, open-label study enrolling a total of up to 23 patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and nature of dose-limiting toxicities</measure>
    <time_frame>Length and study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence, nature, and severity of adverse events</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vital signs</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of infusion reactions</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical laboratory results</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-PRO95780 antibodies</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO95780</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed CRC with evidence of locally advanced recurrent or metastatic
             disease and measurable tumor lesions

          -  Life expectancy &gt; 3 months

          -  For patients of reproductive potential (males and females), use of reliable means for
             contraception throughout the trial and for 6 months following their final exposure to
             study treatment

          -  Willingness and capability to be accessible for study follow-up

        Exclusion Criteria:

          -  Prior 5-FU, capecitabine, and/or oxaliplatin treatment with the exception of: prior
             oxaliplatin treatment≤ 6 weeks in the advanced or metastatic setting; prior treatment
             with 5-FU, capecitabine, and/or oxaliplatin in the adjuvant setting if relapse
             occurred &gt; 6 months from concluding adjuvant therapy

          -  Peripheral neuropathy Grade ≥ 2

          -  Prior radiotherapy to a measurable metastatic lesion(s) to be used for response
             assessment, unless the lesion has progressed subsequent to the radiotherapy

          -  Radiotherapy to a peripheral lesion within 14 days prior to Cycle 1, Day 1, or
             radiotherapy to a thoracic, abdominal, or pelvic field within 28 days prior to Cycle
             1, Day 1

          -  Chemotherapy, hormonal therapy, or immunotherapy within 4 weeks prior to Cycle 1, Day
             1

          -  Evidence of clinically detectable ascites

          -  Other invasive malignancies within 5 years prior to Cycle 1, Day 1

          -  History or evidence upon physical examination of active central nervous system (CNS)
             disease

          -  Current or recent participation in another experimental drug study

          -  Clinically significant cardiovascular disease, New York Heart Association (NYHA) Grade
             II or greater congestive heart failure, serious cardiac arrhythmia within 1 year prior
             to Cycle 1, Day 1, or Grade II or greater peripheral vascular disease

          -  Active infection requiring parenteral antibiotics

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to Cycle 1, Day 1, fine needle aspirations within 7 days prior to Cycle 1, Day
             1, or anticipation of need for major surgical procedure during the course of the study

          -  Known or suspected to be positive for the human immunodeficiency virus (HIV)

          -  Known to be positive for hepatitis C or hepatitis B surface antigen

          -  Inadequately controlled hypertension

          -  Prior history of hypertensive crisis or hypertensive encephalopathy

          -  History of arterial thromboembolic event 6 months prior to Cycle 1, Day 1

          -  History of abdominal fistula or gastrointestinal perforation within 6 months prior to
             Cycle 1, Day 1

          -  Bleeding diathesis or coagulopathy

          -  Pregnancy (positive pregnancy test) or breast feeding

          -  Serious, non-healing wound, ulcer, or bone fracture
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chia Portera, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2009</study_first_submitted>
  <study_first_submitted_qc>February 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2009</study_first_posted>
  <last_update_submitted>June 29, 2010</last_update_submitted>
  <last_update_submitted_qc>June 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2010</last_update_posted>
  <responsible_party>
    <name_title>Clinical Trials Posting Group</name_title>
    <organization>Genentech, Inc.</organization>
  </responsible_party>
  <keyword>CRC</keyword>
  <keyword>Colon cancer</keyword>
  <keyword>Avastin</keyword>
  <keyword>APM4566g</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

